Preventive effect of sodium bicarbonate Ringer's solution on post-contrast acute kidney injury in patients undergoing percutaneous coronary intervention

碳酸氢钠林格氏液对经皮冠状动脉介入治疗患者造影后急性肾损伤的预防作用

阅读:3

Abstract

BACKGROUND: Post-contrast acute kidney injury (PC-AKI) is a common complication of coronary angiography (CAG) and percutaneous coronary interventions (PCI). Sodium bicarbonate Ringer's solution (BRS) has been shown to reduce the incidence of postoperative AKI and the risk of acid-base disorder in surgical and critically ill patients. There is no research data of BRS in the field of PC-AKI. Therefore, this study aimed to evaluate the efficacy and safety of BRS in the prevention of PC-AKI. METHODS: Patients with coronary atherosclerotic heart disease and stage 2-3b chronic kidney disease (CKD) who underwent CAG or PCI were prospectively enrolled and randomly assigned to BRS group or normal saline (NS) group from February 2024 to October 2024. The patients were given BRS or NS for hydration at 1mL/kg/h from 3 h before to 4 h after CAG/PCI. Serum creatinine (Scr), cystatin C (Cys-C) and neutrophil gelatinase-associated apolipoprotein (NGAL) were measured within 3 days before and 48 h after iodinated contrast agent exposure. The primary endpoint was PC-AKI, and the secondary endpoints were the need of renal replacement therapy (RRT) and major adverse cardiovascular events (MACEs) within 30 days after CAG/PCI. The correlation between BRS and PC-AKI was analyzed by multivariate logistic regression. RESULTS: The baseline characteristics of patients in the two groups were similar, and the changes of Cys-C, NGAL, and electrolytes before and after CAG/PCI were not statistically significant. PC-AKI occurred in 1 patient (1.3%) in BRS group and 7 patients (9.3%) in NS group, and the difference was statistically significant (P = 0.029). Multivariate logistic regression showed that there was an approaching statistical trend of BRS to reduce the incidence of PC-AKI (P = 0.054). CONCLUSION: BRS might be more suitable than NS in reducing the incidence of PC-AKI for patients with mild-to-moderate renal dysfunction who underwent CAG/PCI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。